ReviewExperimental biology and medicine (Maywood, N.J.)2021
Microengineered systems with iPSC-derived cardiac and hepatic cells to evaluate drug adverse effects.
Review in Experimental biology and medicine (Maywood, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 17 citations in OpenAlex.
- Next-Generation In Vitro Pulmonary Platforms for Respiratory Disease Modelling and Therapeutic Development: Current Advances and Future Prospects.Medicina (Kaunas, Lithuania) · 2026Review
- Smarter stem cells: how AI is supercharging iPSC technology.Cell and tissue research · 2025Review
- Human-Induced Pluripotent Stem Cell Models for Amyloid Cardiomyopathy: From Mechanistic Insights to Therapeutic Discovery.Journal of cardiovascular development and disease · 2025Review
- Nonclinical Human Cardiac New Approach Methodologies (NAMs) Predict Vanoxerine-Induced Proarrhythmic Potential.Journal of cardiovascular development and disease · 2025Article
- Research Progress on Neural Cell Culture Systems.Current neuropharmacology · 2025Review
- Translational Utility of Organoid Models for Biomedical Research on Gastrointestinal Diseases.Stem cell reviews and reports · 2024Review
- The development of in vitro organotypic 3D vulvar models to study tumor-stroma interaction and drug efficacy.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- An Insight on Microfluidic Organ-on-a-Chip Models for PMACS omega · 2024Review
- Human Hepatic Spheroid Coculture Model for the Assessment of Drug-Induced Liver Injury.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Harnessing three-dimensional (3D) cell culture models for pulmonary infections: State of the art and future directions.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Progress of research on tumor organoids: A bibliometric analysis of relevant publications from 2011 to 2021.Frontiers in oncology · 2023Article
- New science, drug regulation, and emergent public health issues: The work of FDA's division of applied regulatory science.Frontiers in medicine · 2022Review
- Emerging technologies and their impact on regulatory science.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Establishment and characterization of organoids from a patient with adenomyoepithelioma of the breast.Bioengineered · 2021Article
- 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration.Clinical and translational science · 2021Review
- Single-Use Bioreactors for Human Pluripotent and Adult Stem Cells: Towards Regenerative Medicine Applications.Bioengineering (Basel, Switzerland) · 2021Review
- The paradigm of stem cell secretome in tissue repair and regeneration: Present and future perspectives.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic and cardiac drug adverse effects are among the leading causes of attrition in drug development programs, in part due to predictive failures of current animal or
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.